Details for Patent: 10,912,771
✉ Email this page to a colleague
Which drugs does patent 10,912,771 protect, and when does it expire?
Patent 10,912,771 protects INGREZZA and INGREZZA SPRINKLE and is included in two NDAs.
This patent has seventy patent family members in eleven countries.
Summary for Patent: 10,912,771
| Title: | Methods for the administration of certain VMAT2 inhibitors |
| Abstract: | Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-.alpha.-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2- ,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer. |
| Inventor(s): | O'Brien; Christopher F. (San Diego, CA), Bozigian; Haig P. (San Diego, CA) |
| Assignee: | Neurocrine Biosciences, Inc. (San Diego, CA) |
| Application Number: | 17/073,304 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 10,912,771
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | A METHOD OF TREATING HUNTINGTON'S CHOREA | ⤷ Sign Up | |||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Sign Up | |||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER | ⤷ Sign Up | |||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | A METHOD OF TREATING HUNTINGTON'S CHOREA | ⤷ Sign Up | |||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER | ⤷ Sign Up | |||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF TARDIVE DYSKINESIA | ⤷ Sign Up | |||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD OF TREATING HUNTINGTON'S CHOREA | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,912,771
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017395700 | ⤷ Sign Up | |||
| Australia | 2017395701 | ⤷ Sign Up | |||
| Australia | 2017395702 | ⤷ Sign Up | |||
| Australia | 2017395703 | ⤷ Sign Up | |||
| Australia | 2017395704 | ⤷ Sign Up | |||
| Australia | 2022203201 | ⤷ Sign Up | |||
| Australia | 2022203327 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
